Agilent Technologies and Exact Sciences are selling Resolution Bioscience to Exact Sciences. The financial details of the deal have not been disclosed. Resolution Bioscience, a developer of next-generation sequencing-based precision oncology solutions, was acquired by Agilent in 2021. The acquisition will enable Exact Sciences to integrate Resolution Bioscience’s diagnostics into its Precision Oncology portfolio, expanding its capabilities in cancer diagnostic testing.
Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.
“We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, senior vice president, Agilent, and president, Diagnostics and Genomics Group. “Exact is a leading centralized laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a strategic fit for them. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction.”
“We are excited to work with the Resolution Bioscience team to integrate their innovative diagnostics into our Precision Oncology portfolio,” said Brian Baranick, general manager of Precision Oncology at Exact Sciences. “Resolution Bioscience’s high-quality liquid therapy selection platform perfectly complements our OncoExTra test, allowing Exact Sciences to help more cancer patients determine their best treatment options.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.
Source: Bio Space